By Colin Kellaher
Mineralys Therapeutics on Monday reported positive topline results from a pair of pivotal studies of its lorundrostat drug candidate for the treatment of uncontrolled or resistant hypertension.
Mineralys said its Phase 3 Launch-HTN and Phase 2 Advance-HTN studies achieved statistical significance and were clinically meaningful in their pre-specified primary efficacy endpoints while showing a favorable safety and tolerability profile.
The Radnor, Pa., clinical-stage biopharmaceutical company said it believes the clinical profile observed for lorundrostat supports the potential regulatory approval of the drug, which it said has the potential to be a transformative new therapy for the roughly 15 million to 20 million people in the U.S. living with uncontrolled hypertension.
Trading in shares of Mineralys, which closed Friday at $10.52, was halted premarket on Monday.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
March 10, 2025 07:19 ET (11:19 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.